Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Alabama Precertification …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - AlabamaPolicy N/A

    Provider-Administered Precertification Drug List

    Customize your policy alerts

    Sign up for all blue cross blue shield - alabama policy alerts

    Know when blue cross blue shield - alabama releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists provider‑administered drugs that require precertification when given in provider offices, outpatient facilities, or home health settings; gene therapy/cellular immunotherapy products require precertification in any setting. Also notes limited pharmacy access rules for PEEHIP members.

    Policy Summary
    PayerBlue Cross Blue Shield - Alabama
    PolicyProvider-Administered Precertification Drug List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification prior to administering listed provider-administered drugs in office, outpatient facility, or home health settings (gene therapy products require PA in any setting).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    200+drugs listed on the precertification roster (approximate)
    Gene Therapy/Cellular Immunotherapyproducts requiring PA in any setting

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Avastin (oncology only)
    Avastin PA limited to oncology indications
    Monthlylist update frequency
    Lemtrada/Synagis/SpravatoPEEHIP exceptions

    Precertification and Coverage Rules

    Precertification requirement

    Covered when ALL of the following are met

    Precertification requirements: Drug is on the Provider-Administered Precertification Drug List AND precertification obtained prior to administration

    Gene Therapy/Cellular Immunotherapy products (marked '+') require precertification in any place of treatment; Avastin requires PA for oncology indications only.

    For PEEHIP members, provider-administered medications listed on the Provider-Administered Precertification Drug List are excluded from access through a specialty pharmacy and must be obtained via buy-and-bill, except for specified exceptions. Lemtrada requires use of a specialty pharmacy, while Synagis and Spravato may be obtained either by buy-and-bill or through a specialty pharmacy. This exclusion applies only to PEEHIP members and the drugs outlined in this policy.

    What Providers Must Do

    Prior Authorization

    Prior Authorization Required

    Precertification is required for provider‑administered drugs listed on the Provider‑Administered Precertification Drug List when administered in a provider's office, outpatient facility, or home health setting. Gene therapy and cellular immunotherapy products (marked with a + on the drug list) require precertification when administered in any place of treatment.

    • Applies to all drugs on the Provider‑Administered Precertification Drug List.
    • Gene therapy/cellular immunotherapy products (+) require PA in any treatment setting.
    Note

    Action Required Before Treatment

    Providers must obtain precertification prior to administration to avoid claim denials or delays in reimbursement.

    • Precertification must be secured before the drug is administered in office, outpatient facility, or home health.
    • Failure to precertify may result in denial of coverage or payment delays.
    Documentation Required

    Documentation / Precertification

    Documentation supporting medical necessity should be submitted with the precertification request. For Gene Therapy/Cellular Immunotherapy products (+), precertification and complete documentation are required regardless of the site of care.

    • Include indication, prior treatments, relevant clinical records, and any specialty‑therapy specific documentation as requested.
    • Gene therapy/cellular immunotherapy products marked with + require PA and full documentation in any setting.
    Billing Rule

    Precertification and Site‑of‑Care Billing Rules

    For PEEHIP members, provider‑administered medications in this policy must be obtained through buy‑and‑bill and are excluded from specialty pharmacy access, except Lemtrada (must use specialty pharmacy), and Synagis and Spravato (may be obtained via buy‑and‑bill or specialty pharmacy). For Avastin, PA is required for oncology indications only.

    • PEEHIP coverage: drugs on this list cannot be accessed through specialty pharmacy — obtain via buy‑and‑bill unless specifically noted.
    • Lemtrada: specialty pharmacy required for PEEHIP members.
    • Synagis and Spravato: may be obtained via buy‑and‑bill or specialty pharmacy for PEEHIP members.
    • Avastin: PA required only for oncology indications.

    Settings Requiring Precertification

    Billing Rule

    Site-of-care precertification requirement

    Precertification is required when these drugs are administered in a provider's office, outpatient facility, or home health setting. Gene Therapy/Cellular Immunotherapy products (marked '+') require precertification in any setting.

    • Applies to provider office, outpatient facility, and home health.
    • Gene therapy/cellular immunotherapy products require PA regardless of site of care.
    • For PEEHIP members, listed provider-administered medications are excluded from specialty pharmacy access and must be obtained via buy-and-bill, with specified exceptions (Lemtrada, Synagis, Spravato).

    List Flags and Notation

    List flags
    Gene therapy/cellular immunotherapy flag'+' indicates Gene Therapy/Cellular Immunotherapy product; these products require precertification when administered in any place of treatment.
    Avastin oncology note'*' indicates Avastin requires prior authorization only for oncology indications.
    List update frequencyProduct list is updated monthly and is subject to change without notice.
    PEEHIP specialty pharmacy exceptionFor PEEHIP members, most provider-administered medications on this list are excluded from specialty pharmacy access and must be obtained via buy-and-bill; exceptions: Lemtrada requires specialty pharmacy; Synagis and Spravato may be obtained either by buy-and-bill or specialty pharmacy.

    Policy Purpose and Scope

    This document is an administrative Provider-Administered Precertification Drug List and is intended to define which provider‑administered drugs require precertification and the settings in which precertification is required; it does not provide clinical practice guidelines or therapeutic indications. Precertification is required when listed drugs are administered in a provider's office, outpatient facility, or home health setting. Products designated as Gene Therapy/Cellular Immunotherapy (marked with a '+') require precertification in any place of treatment. The precertification roster is maintained as the operative administrative list of drugs subject to the Provider-Administered Drug Review Program.

    Policy Summary
    PayerBlue Cross Blue Shield - Alabama
    PolicyProvider-Administered Precertification Drug List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification prior to administering listed provider-administered drugs in office, outpatient facility, or home health settings (gene therapy products require PA in any setting).
    SourceLink
    On This Page
    Precertification and Coverage RulesWhat Providers Must DoSettings Requiring PrecertificationList Flags and NotationPolicy Purpose and Scope